



# THE JOURNAL OF CLINICAL PSYCHIATRY

THE OFFICIAL JOURNAL OF THE AMERICAN SOCIETY OF CLINICAL PSYCHOPHARMACOLOGY

## **Supplementary Material**

**Article Title:** Effect of Concomitant Benzodiazepines on the Antidepressant Effects of Ketamine: Findings From the RAPID Intravenous Ketamine Study

**Author(s):** Anna Feeney, MD; Bettina B. Hoepfner, PhD; Marlene P. Freeman, MD; Martina Flynn, BA; Dan V. Iosifescu, MD; Madhukar H. Trivedi, MD; Gerard Sanacora, MD; Sanjay J. Mathew, MD; Charles DeBattista, MD; Dawn F. Ionescu, MD; Cristina Cusin, MD; George I. Papakostas, MD; Manish K. Jha, MD; and Maurizio Fava, MD

**DOI Number:** <https://doi.org/10.4088/JCP.22m14991>

### **List of Supplementary Material for the article**

1. [Table 1](#) Characteristics of subjects with and without benzodiazepine use

### **Disclaimer**

This Supplementary Material has been provided by the author(s) as an enhancement to the published article. It has been approved by peer review; however, it has undergone neither editing nor formatting by in-house editorial staff. The material is presented in the manner supplied by the author.

**Supplementary Table 1. Characteristics of subjects with and without benzodiazepine use**

			Subjects taking oral benzodiazepines				Subjects not taking oral benzodiazepines			
			N=44 (44.4% of all study subjects)				N=55 (55.6% of all study subjects)			
			Ketamine n=38		Midazolam n=6		Ketamine n=42		Midazolam n=13	
			Mean (SD)	N (%)	Mean (SD)	N (%)	Mean (SD)	N (%)	Mean (SD)	N (%)
Demographics	Age		48.7 (12.2)		48.6 (11.9)		44.1 (12.3)		44.2 (14.8)	
	Female			19 (50.0)		4 (66.7)		19 (45.2)		7 (53.8)
	Hispanic			3 (7.9)		0 (0.0)		0 (0.0)		0 (0.0)
	Race									
		White		37 (97.4)		6 (100.00)		33 (78.6)		12 (92.3)
		Asian		0 (0.0)		0 (0.0)		5 (11.9)		0 (0.0)
		Black		1 (2.6)		0 (0.0)		3 (7.1)		0 (0.0)
		Other		0 (0.0)		0 (0.0)		1 (2.4)		1 (7.7)
	BMI		25.4 (4.3)		26.0 (4.5)		25.3 (4.1)		26.4 (4.2)	
Concomitant medications	Non-benzodiazepine hypnotic			13 (34.2)		1 (16.7)		4 (9.5)		3 (23.1)
	SSRI			19 (50.0)		4 (66.7)		23 (54.8)		6 (46.2)
	SNRI			15 (39.5)		0 (0.0)		8 (19.1)		5 (38.5)
	TCA			2 (5.3)		0 (0.0)		1 (2.3)		0 (0.0)
	Other antidepressants			14 (36.8)		3 (50.0)		26 (61.9)		8 (61.5)

<b>Clinical Severity at Baseline</b>	<b>HAMD-AS</b>		6.8 (2.5)		8.2 (3.3)		5.7 (2.5)		6.0 (2.6)	
	<b>HAM-D-6 - total</b>		12.9 (2.4)		14.2 (2.5)		12.5 (1.6)		12.5 (2.2)	
	<b>MADRS</b>		34.3 (6.9)		38.0 (11.0)		31.5 (5.2)		32.0 (4.9)	
	<b>CGI-S</b>		5.3 (0.7)		5.2 (0.8)		4.8 (0.7)		4.9 (0.8)	

Abbreviations: SD= Standard Deviation, BMI= Body Mass Index, SSRI= Selective Serotonin Reuptake Inhibitor, SNRI= Serotonin Norepinephrine Reuptake Inhibitor, TCA= Tricyclic Antidepressant,

HAMD-AS= Hamilton Depression Rating Scale Anxiety-Somatization factor, HAM-D-6= 6-item Hamilton Depression Rating Scale, MADRS= Montgomery-Asberg Depression Rating Scale, CGI-S= Clinical

Global Impression-Severity scale

Note: Other antidepressants= bupropion, mirtazapine and vortioxetine